In re Asta Medica, S.A.

981 F.2d 1
CourtCourt of Appeals for the First Circuit
DecidedDecember 4, 1992
DocketNos. 92-1663, 92-1726 to 92-1729
StatusPublished
Cited by23 cases

This text of 981 F.2d 1 (In re Asta Medica, S.A.) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Asta Medica, S.A., 981 F.2d 1 (1st Cir. 1992).

Opinion

TORRUELLA, Circuit Judge.

Pursuant to 28 U.S.C. § 1782(a),1 district courts are authorized to assist foreign and international tribunals, and the litigants before such tribunals, in obtaining discovery in the United States for use in proceedings abroad. In this appeal, we examine whether an applicant under 28 U.S.C. § 1782(a) has to make a threshold showing, prior to obtaining such discovery, that the information sought in the United States would generally be subject to discovery in the foreign jurisdiction. The United States District Court for the District of Maine held that such a requirement was not necessary and entered an order granting a request for discovery. In re Application of Asta Medica, S.A., 794 F.Supp. 442 (D.Me.1992). We reverse.

I

Appellant Pfizer, Inc. (“Pfizer”) is involved in patent litigation proceedings in Europe against Asta Medica, S.A., Laboratories Sarget, S.A., Dagra, BV, and Napp Laboratories, Ltd. (collectively “the foreign companies”), four European pharmaceutical companies. Litigation is pending in France, Belgium, England and the Netherlands over a patent owned by Pfizer for several methods to manufacture the antibiotic doxycycline.

The process of the patent at issue involves homogeneous catalyzed production of doxycycline. The foreign companies assert that Pfizer derived the invention of the process from an Italian company, Anker-farm, S.p.A. (“Ankerfarm”), in the early 1970’s while Pfizer and Ankerfarm negotiated a proposed joint venture involving the new process. In 1971 and 1972, Pfizer employees met with Ankerfarm employees working on the doxycycline processing technology in Milan and allegedly learned the characteristics of the invention. Although the joint venture between Anker-farm and Pfizer never materialized, Pfizer obtained its own patents on the process. The foreign companies want to establish that the process was in the public domain before Pfizer applied for the patent and therefore, Pfizer’s patents are invalid. They, therefore, seek to obtain documents and the testimony of former Pfizer employees who were involved in Pfizer’s transactions with Ankerfarm. In July of 1991, they filed an ex parte application under 28 U.S.C. § 1782 in the United States District Court for the District of Maine requesting a subpoena compelling David W. Moriarty, a retired employee of Pfizer Inc., to testify [3]*3by deposition and produce documents.2 On July 24, 1991, Magistrate Judge Cohen granted the ex parte application and the subpoena was issued. On August 12,1991, however, Pfizer moved to quash the subpoena on the ground that a private party invoking a district court’s assistance under Section 1782 had to show that the requested information was discoverable in the foreign jurisdiction. In an affidavit, Pfizer’s general patent counsel asserted that the information sought by the foreign companies in fact would not be available and could not be used in the foreign proceedings.

The foreign companies opposed Pfizer’s motion by filing affidavits from foreign lawyers asserting that the evidence was obtainable in each country if the witness was found there. Pfizer responded with affidavits from foreign lawyers maintaining that as a general matter there is no pretrial availability of information from non-party witnesses in France, Belgium, England and the Netherlands. Only in an extraordinary case, where a litigant has obtained judicial approval, may a litigant compel the testimony or production of documents of a non-party witness.

On September 10, 1991, Magistrate Judge Cohen granted Pfizer’s motion to quash and rescinded the July 24, 1991 order issuing the subpoena. The foreign companies sought review of the Magistrate Judge’s order before the district court.

On May 22,1992, the district court issued an order vacating the Magistrate Judge’s decision and granting the application for an order to take testimony and a subpoena duces tecum. In re Application of Asta Medica, S.A., 794 F.Supp. 442 (D.Me.1992).3 Pfizer appealed and filed a motion for a stay pending appeal. We granted Pfizer’s motion for a stay and heard the appeal on an expedited basis.

II

The proceedings in Europe involve different parties and patents and various stages of prosecution. Since a description of these proceedings is not critical to the resolution of this appeal, we provide only a limited summary of the litigation pending in each country.

A. Proceedings in France

In 1980, Pfizer and its French subsidiary sued the French applicant, Laboratories Sarget, S.A., (“Sarget”) for patent infringement. In 1988, the trial court ruled that there was no patent infringement. In April of 1990, the Paris Court of Appeal overturned that ruling and appointed an expert to determine the damages question. An appeal filed by Sarget is currently pending before the Cour de Cassation, France’s highest court.

Pfizer asserts that the validity or infringement of the patent is not at issue since the briefing stage of the appeal is complete and the authority of the Cour de Cassation is limited only to issues of law. The foreign companies argue that validity of the patent is relevant to the damages issue.

Pfizer also sued Hovione for patent infringement in Lyon, France. The trial court in Lyon found no infringement, and Pfizer appealed. The companies argue [4]*4that the evidence sought is pertinent because Hovione is asserting on appeal that Pfizer’s patent is invalid.

Finally, Sarget and one of its subsidiaries sued Pfizer in Bordeaux petitioning the court to nullify Pfizer’s French patent.4

B. Proceedings in England

Napp Laboratories, Ltd. (“Napp”) has filed a petition asking for the revocation of Pfizer’s United Kingdom patents.

According to Pfizer, it has no commercial interest in the English patent and the patent “is already subject to licenses of right that can be obtained by anyone in England.” Appellant’s Brief at 12. Pfizer asserts that Napp has brought a sham nullity proceeding in England to show in the Section 1782 application that there is a British “proceeding.” Napp argues that “[t]he record in the United Kingdom proceeding is also open.” Appellees' Brief at 12.

C. Proceedings in Belgium

Pfizer sued Asta Medica, S.A. (“Asta”) claiming that Asta infringed its Belgian process patent. The Belgian court referred the matter to a panel of experts who found no infringement of Pfizer’s patent. Pfizer is contesting this finding.

D. Proceedings in the Netherlands

A dispute over an application filed by Pfizer for a Dutch patent is pending before the Patent Council in The Hague. The application was originally filed by Anker-farm in 1973 and assigned to Pfizer by Glaxo Limited Group, a British pharmaceutical firm, pursuant to an agreement dated March 12, 1984. Dagra, BV (“Dagra”) is opposing the grant of the patent. On September 10, 1988, Pfizer gave Dagra notice of its intent to sue for infringement upon issuance of its patent.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Jimenez-Espino v. Kijakazi
E.D. Washington, 2023
(PC) Osborne v. Gates
E.D. California, 2022
Thompson v. Saukhla
E.D. California, 2021
Smith v. Saul
E.D. Washington, 2021
Schlich v. Broad Inst., Inc. (In Re Schlich)
893 F.3d 40 (First Circuit, 2018)
NH Right to Life v. US DHHS
2013 DNH 132 (D. New Hampshire, 2013)
Sensor Sys v. FAA
2012 DNH 083 (D. New Hampshire, 2012)
Shafmaster v. USA
2012 DNH 091 (D. New Hampshire, 2012)
Brandi-Dohrn v. IKB DEUTSCHE INDUSTRIEBANK AG
673 F.3d 76 (Second Circuit, 2012)
Sensor Sytems v FAA
2012 DNH 037 (D. New Hampshire, 2012)
In Re Application of Chevron Cor.
762 F. Supp. 2d 242 (D. Massachusetts, 2010)
United States v. McMullin
2007 DNH 085 (D. New Hampshire, 2007)
Parks v. Tatarinowicz
2005 DNH 149 (D. New Hampshire, 2005)
Wilkinson v. Chao
2003 DNH 199 (D. New Hampshire, 2003)
Anheuser-Busch v. Caught-on-Bleu
2003 DNH 127 (D. New Hampshire, 2003)
Hill Design v. Vivian Hodgdon, et al.
2003 DNH 059 (D. New Hampshire, 2003)
In Re Ishihara Chemical Co., Ltd.
121 F. Supp. 2d 209 (E.D. New York, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
981 F.2d 1, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-asta-medica-sa-ca1-1992.